氨己烯酸片中国上市时间

Vigabatrin is an analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). It reduces the degradation of GABA by irreversibly binding to GABA transaminase, thereby increasing the level of GABA in the central nervous system and exerting anti-epileptic effects. The indications of vigabatrin tablets Vigabatrin include monotherapy for infantile spasms in children aged 1 month to 2 years old and add-on treatment in patients with complex partial epilepsy over 10 years old. Vigabatrin is currently recommended as the first-line treatment for infantile spasms, and the drug of choice for epileptic spasms also includes Vigabatrin.

The development of vigabatrin tablets Vigabatrin originated in the 1980s. Its active pharmaceutical ingredient is vigabatrin (vigabatrin). Its mechanism of action is to irreversibly inhibit GABA aminotransferase (GABA-T) and increase the concentration of GABA in the brain.

In terms of usage and dosage, the initial dose of Vigabatrin tablets for the treatment of infantile spasms (1 month to 2 years old) is 50 mg/kg/day, taken orally, in two divided doses, with or without food. Vigabatrin dosage can be increased every 3 days in increments of 25 to 50 mg/kg/day, up to a maximum of 150 mg/kg/day. The maximum daily dosage for adults is 2-3g. It is appropriate to start with 1g a day. Then, depending on the response after taking the medication, if the response is good, it can be increased by 0.5g every week, and finally reaches a dosage of 2-3g per day.

Time to launch Vigabatrin tablets in China: So far, French Sanofi Vigabatrin tablets have been launched in many countries and regions, but they have not yet been approved by the National Medical Products Administration (NMPA) to be officially launched in China. Therefore, patients who currently need this drug for treatment can only first purchase drugs overseas to meet their needs.

The incidence of visual field defects was high (approximately one third) in patients treated with Vigabatrin. This often occurs after using Vigabatrin for several months to several years. Visual field defects can be severe, which can have real consequences for the patient. Most patients with visual field loss have no obvious symptoms. In adult patients, peripheral neuropathy developed after treatment with Vigabatrin, manifested by numbness or tingling in the toes or feet, diminished vibration or position sensation in the distal lower extremities, or progressive loss of reflexes. Patients taking the antiepileptic drugs Vigabatrin Tablets and Vigabatrin are at increased risk for suicidal ideation/behavior. Monitor changes in the patient's behavior and notify the doctor immediately if suicidal thoughts or symptoms of depression occur.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: